[Date Prev][Date Next][Thread Prev][Thread Next][Date Index ][Thread Index ]

Reuters-WHO focuses leprosy elimina

Subject: Reuters-WHO focuses leprosy elimination program

This is a multi-part message in MIME format.

------=_NextPart_000_004A_01BE8C43.10CB29C0
Content-Type: multipart/alternative;
	boundary="----=_NextPart_001_004B_01BE8C43.10CB29C0"


------=_NextPart_001_004B_01BE8C43.10CB29C0
Content-Type: text/plain;
	charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable

Tuesday April 20 2:11 PM ET=20

WHO focuses leprosy elimination program
NEW YORK, Apr 20 (Reuters Health) -- In all but a handful of countries, =
leprosy has nearly been eliminated as a public health problem, the World =
Health Organization (WHO) reported Monday.

``Since 1985, the use of multidrug therapy to treat and cure patients =
has already reduced the global prevalence of the disease by 85%, and the =
number of countries with more than one case per 10,000 (population) has =
dropped from 122 to only 28 at the start of this year,'' WHO officials =
said in a press release.

However, the organization estimates that, by the end of 2000, =
approximately 10 countries will still have more than the target level of =
one leprosy case per 10,000 people.

``The 13 (countries) recognized at present as 'top endemic countries' =
are, in order of prevalence, India, Brazil, Indonesia, Myanmar, =
Madagascar, Nigeria, Mozambique, Nepal, Ethiopia, Democratic Republic of =
Congo, Niger, Guinea and Cambodia,'' WHO reports.

Health officials estimate that nearly 2 million people have undiagnosed =
leprosy. Of these, 90% live in one of these 13 countries.

Last week a Leprosy Elimination Advisory Group met at WHO headquarters =
in Geneva to discuss how to overcome the barriers to distributing =
multidrug treatment in endemic countries. According to the press =
release, these include lack of access to patients in remote areas, =
bureaucratic delays, and a lack of medical personnel.=20



------=_NextPart_001_004B_01BE8C43.10CB29C0
Content-Type: text/html;
	charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML><HEAD>
<META content=3D"text/html; charset=3Diso-8859-1" =
http-equiv=3DContent-Type><BASE=20
href=3D"file://C:\Program Files\Common Files\Microsoft =
Shared\Stationery\">
<STYLE>BODY {
	COLOR: #000000; FONT-FAMILY: "Arial"; FONT-SIZE: 12pt; MARGIN-BOTTOM: =
0em; MARGIN-TOP: 0em
}
P.msoNormal {
	COLOR: #000000; FONT-FAMILY: "Arial"; FONT-SIZE: 12pt; MARGIN-BOTTOM: =
0em; MARGIN-TOP: 0em
}
LI.msoNormal {
	COLOR: #000000; FONT-FAMILY: "Arial"; FONT-SIZE: 12pt; MARGIN-BOTTOM: =
0em; MARGIN-TOP: 0em
}
PRE {
	COLOR: #000000; FONT-FAMILY: "Arial"; FONT-SIZE: 12pt; MARGIN-BOTTOM: =
0em; MARGIN-TOP: 0em
}
BLOCKQUOTE {
	COLOR: #000000; FONT-FAMILY: "Arial"; FONT-SIZE: 12pt; MARGIN-BOTTOM: =
0em; MARGIN-TOP: 0em
}
A {
	COLOR: #000000; FONT-FAMILY: "Arial"; FONT-SIZE: 12pt; MARGIN-BOTTOM: =
0em; MARGIN-TOP: 0em
}
MENU {
	COLOR: #000000; FONT-FAMILY: "Arial"; FONT-SIZE: 12pt; MARGIN-BOTTOM: =
0em; MARGIN-TOP: 0em
}
DD {
	COLOR: #000000; FONT-FAMILY: "Arial"; FONT-SIZE: 12pt; MARGIN-BOTTOM: =
0em; MARGIN-TOP: 0em
}
UL {
	COLOR: #000000; FONT-FAMILY: "Arial"; FONT-SIZE: 12pt; MARGIN-BOTTOM: =
0em; MARGIN-TOP: 0em
}
DT {
	COLOR: #000000; FONT-FAMILY: "Arial"; FONT-SIZE: 12pt; MARGIN-BOTTOM: =
0em; MARGIN-TOP: 0em
}
DIR {
	COLOR: #000000; FONT-FAMILY: "Arial"; FONT-SIZE: 12pt; MARGIN-BOTTOM: =
0em; MARGIN-TOP: 0em
}
ADDRESS {
	COLOR: #000000; FONT-FAMILY: "Arial"; FONT-SIZE: 12pt; MARGIN-BOTTOM: =
0em; MARGIN-TOP: 0em
}
H1 {
	COLOR: #000000; FONT-FAMILY: "Arial"; FONT-SIZE: 12pt; MARGIN-BOTTOM: =
0em; MARGIN-TOP: 0em
}
H2 {
	COLOR: #000000; FONT-FAMILY: "Arial"; FONT-SIZE: 12pt; MARGIN-BOTTOM: =
0em; MARGIN-TOP: 0em
}
H3 {
	COLOR: #000000; FONT-FAMILY: "Arial"; FONT-SIZE: 12pt; MARGIN-BOTTOM: =
0em; MARGIN-TOP: 0em
}
H4 {
	COLOR: #000000; FONT-FAMILY: "Arial"; FONT-SIZE: 12pt; MARGIN-BOTTOM: =
0em; MARGIN-TOP: 0em
}
H5 {
	COLOR: #000000; FONT-FAMILY: "Arial"; FONT-SIZE: 12pt; MARGIN-BOTTOM: =
0em; MARGIN-TOP: 0em
}
H6 {
	COLOR: #000000; FONT-FAMILY: "Arial"; FONT-SIZE: 12pt; MARGIN-BOTTOM: =
0em; MARGIN-TOP: 0em
}
HR {
	COLOR: #000000; FONT-FAMILY: "Arial"; FONT-SIZE: 12pt; MARGIN-BOTTOM: =
0em; MARGIN-TOP: 0em
}
</STYLE>

<META content=3D"MSHTML 5.00.2014.210" name=3DGENERATOR></HEAD>
<BODY background=3Dcid:004901be8bf7$a0da5a00$b506fea9@xxxxxxx =
bgColor=3D#ffffff>
<DIV>
<DIV>Tuesday April 20 2:11 PM ET </DIV>
<DIV>&nbsp;</DIV>
<DIV>WHO focuses leprosy elimination program<BR>NEW YORK, Apr 20 =
(Reuters=20
Health) -- In all but a handful of countries, leprosy has nearly been =
eliminated=20
as a public health problem, the World Health Organization (WHO) reported =

Monday.</DIV>
<DIV>&nbsp;</DIV>
<DIV>``Since 1985, the use of multidrug therapy to treat and cure =
patients has=20
already reduced the global prevalence of the disease by 85%, and the =
number of=20
countries with more than one case per 10,000 (population) has dropped =
from 122=20
to only 28 at the start of this year,'' WHO officials said in a press=20
release.</DIV>
<DIV>&nbsp;</DIV>
<DIV>However, the organization estimates that, by the end of 2000, =
approximately=20
10 countries will still have more than the target level of one leprosy =
case per=20
10,000 people.</DIV>
<DIV>&nbsp;</DIV>
<DIV>``The 13 (countries) recognized at present as 'top endemic =
countries' are,=20
in order of prevalence, India, Brazil, Indonesia, Myanmar, Madagascar, =
Nigeria,=20
Mozambique, Nepal, Ethiopia, Democratic Republic of Congo, Niger, Guinea =
and=20
Cambodia,'' WHO reports.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Health officials estimate that nearly 2 million people have =
undiagnosed=20
leprosy. Of these, 90% live in one of these 13 countries.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Last week a Leprosy Elimination Advisory Group met at WHO =
headquarters in=20
Geneva to discuss how to overcome the barriers to distributing multidrug =

treatment in endemic countries. According to the press release, these =
include=20
lack of access to patients in remote areas, bureaucratic delays, and a =
lack of=20
medical personnel. </DIV>
<DIV><BR>&nbsp;</DIV></DIV></BODY></HTML>

------=_NextPart_001_004B_01BE8C43.10CB29C0--

------=_NextPart_000_004A_01BE8C43.10CB29C0
Content-Type: image/gif;
	name="tech.gif"
Content-Transfer-Encoding: base64
Content-ID: <004901be8bf7$a0da5a00$b506fea9@xxxxxxx>
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------=_NextPart_000_004A_01BE8C43.10CB29C0--